Coronavirus good news thread

Liamo said:
As you say though, this is not necessarily all bad news.
Click to expand...
There's a full discussion of this case on Dr. John Campbell's YouTube channel.

He also doesn't think it's too concerning given that it's one case out of 24 million infections and that this person did not seroconvert (create antibodies) the first time but did the second, indicating that the person's immune system protected them the second time round.

 
In Sweden just 15 people in ICU nationally. In the last month deaths per day only reached 5 on one occassion. Most days just 1 or 2. They are running negative excess deaths and have been for a while. Self-testing did temporarily raise cases, though most were amongst the young and mild. Even those numbers are dropping now. They are maintaining the same regime into the autumn but it would appear that the epidemic as a serious disease well and truly over for Sweden. Finally Stockholm's emergency care regime has finished and reverted to normal staffing/hours and the ICU doctors and nurses are finally able to get their lives back.

Daily graphs here. Top is infections. Middles is ICU admissions. Bottom is deaths.
https://experience.arcgis.com/experience/09f821667ce64bf7be6f9f87457ed9aa
 
asredastheycome said:
Serious question. How does that work then. You're either dead or, preferably, alive
Click to expand...

Excess deaths works on an average across a certain number of years. So if the average of 2014-2019 is 2000 deaths in July and 2020 has 1800 deaths we are running negative (-200 compared to the average).
 
The results for a new drug appear pretty impressive -

OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

Those who were treated with SACCOVIDTM and corticosteroids recovered 10 days earlier than those who received corticosteroids and placebo (median time to recovery 5 days vs 15 days)

https://www.biospace.com/article/re...ugh-in-treating-severe-and-critical-covid-19/
 
A study published in the Lancet gives evidence that a novel, human recombinant soluble ACE2 drug called APN01:
has a dual action – it blocks the virus and can protect the lung, blood vessels and the heart from injury via its enzyme function
[and]
showing that this dual function in one drug might be one of the most rational and promising therapeutic approaches we have.
Click to expand...

First data on using a therapeutic form of ACE2 to treat CoVid-19
 
You must log in or register to reply here.
Back
Top